talazoparib,rucaparib,olaparib,enzalutamide,abiraterone
clovis oncology,merck,pfizer,astrazeneca,astellas
['rucaparib', 'brca', 'crpc', 'biomarker', 'olaparib', 'talazo', 'talapro-2', 'marker ']
talapro-2 rpfs for talazoparib/enza in unselected crpc with more benefit in hrr as with olaparib/abi. titron-3 showed rucaparib alone rpfs, particularly in brcas. atm fails to enrich again. os not +ve yet in either. the biomarker is important for parpi in crpc imo #ascogu23
Interested in Urology Cancers, biomarkers and drug development.